Suppression of tumorigenicity-2 (ST2) is a promising biomarker in heart transplantation.
biomarker
heart donor
heart graft dysfunction
Journal
Clinical transplantation
ISSN: 1399-0012
Titre abrégé: Clin Transplant
Pays: Denmark
ID NLM: 8710240
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
revised:
15
01
2022
received:
18
10
2021
accepted:
08
02
2022
pubmed:
22
2
2022
medline:
14
5
2022
entrez:
21
2
2022
Statut:
ppublish
Résumé
To evaluate the association between donors' and recipients' serum levels of soluble ST2 (sST2) and recipients' outcome after heart transplantation (HT). Blood samples were collected in 50 heart donors before organ procurement and in 50 recipients before HT (D0), a week after HT (D7) and at every first year's endomyocardial biopsy (EMB); sST2 levels were evaluated by ELISA. Donors who sustained a cardiac arrest, had significantly higher sST2 levels. Recipients on national high emergency waiting list had significantly higher preoperative sST2 levels compared to recipients who did not. Recipients with postoperative sepsis or continuous renal replacement therapy had significantly higher sST2 levels at D7. Recipients who needed a postoperative ECMO for allograft dysfunction had significantly higher sST2 levels in their corresponding donors. Recipients who died during the hospitalization after the transplantation had significantly higher sST2 levels at D7 compared to recipients who did not. No difference was observed in sST2 levels in recipients who had mild allograft rejection and recipient who did not. Higher sST2 levels in donors are associated to allograft dysfunction requiring ECMO in recipients; higher postoperative sST2 levels in recipients are associated with in-hospital mortality.
Sections du résumé
BACKGROUND
To evaluate the association between donors' and recipients' serum levels of soluble ST2 (sST2) and recipients' outcome after heart transplantation (HT).
METHODS
Blood samples were collected in 50 heart donors before organ procurement and in 50 recipients before HT (D0), a week after HT (D7) and at every first year's endomyocardial biopsy (EMB); sST2 levels were evaluated by ELISA.
RESULTS
Donors who sustained a cardiac arrest, had significantly higher sST2 levels. Recipients on national high emergency waiting list had significantly higher preoperative sST2 levels compared to recipients who did not. Recipients with postoperative sepsis or continuous renal replacement therapy had significantly higher sST2 levels at D7. Recipients who needed a postoperative ECMO for allograft dysfunction had significantly higher sST2 levels in their corresponding donors. Recipients who died during the hospitalization after the transplantation had significantly higher sST2 levels at D7 compared to recipients who did not. No difference was observed in sST2 levels in recipients who had mild allograft rejection and recipient who did not.
CONCLUSIONS
Higher sST2 levels in donors are associated to allograft dysfunction requiring ECMO in recipients; higher postoperative sST2 levels in recipients are associated with in-hospital mortality.
Substances chimiques
Biomarkers
0
IL1RL1 protein, human
0
Interleukin-1 Receptor-Like 1 Protein
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14616Informations de copyright
© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Tominaga S. A putative protein of a growth specific cDNA from BALB/c 3T3 cells is highly similar to the extracellular portion of mouse interleukin-1 receptor. FEBS Lett. 1989;258:301-304.
Bergers G, Reikerstorfer A, Braselmann S, et al. Alternative promoter usage of the fos-responsive gene Fit-1 generates RNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor. EMBO J. 1994;13:1176-1188.
Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1- like cytokine that signals via the IL-1 receptor related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23:479-490.
Oshikawa K, Kuroiwa K, Tago K, et al. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am J Respir Crit Care Med. 2001;164:277-281.
Tajima S, Oshikawa K, Tominaga S, Sugiyama Y. The increase in serum soluble ST2 protein upon acute exacerbation of idiopathic pulmonary fibrosis. Chest. 2003;124:1206-1214.
Beltrán CJ, Núñez LE, Díaz-Jiménez D, et al. Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2010;16:1097-1107.
Brunner M, Krenn C, Roth G, et al. Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma. Intensive Care Med. 2004;30:1468-1473.
Palmer G, Talabot-Ayer D, Lamacchia C, et al. Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum. 2009;60:738-749.
Yin H, Huang BJ, Yang H, et al. Pretreatment with soluble ST2 reduces warm hepatic ischemia/reperfusion injury. Biochem Biophys Res Commun. 2006;351:940-946.
Weinberg EO, Shimpo M, De Keulenaer GW, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation. 2002;106:2961-2966.
Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest. 2007;117:1538-1549.
Shimpo M, Morrow DA, Weinberg EO, et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation. 2004;109:2186-2190.
Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation. 2003;107:721-726.
Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant. 2005;24:1710-1720.
Mehra MR, Crespo-Leiro MG, Dipchand A, et al. International society for heart and lung transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy-2010. J Heart Lung Transplant. 2010;29:717-727.
Madam S, Saeed O, Shin J, et al. Donor troponin and survival after cardiac transplantation an analysis of the united network of organ sharing registry. Circ Heart Fail. 2016;9:e002909.
Freundt M, Philipp A, Kolat P, et al. Impact of elevated donor troponin I as predictor of adverse outcome in adult heart transplantation: a single-center experience. Thorac Cardiovasc Surg. 2018;66:417-424.
Amir NL, Gerber IL, Edmond JJ, Langlands JM, Richards AM, Ruygrok PN. Plasma B-type natriuretic peptide levels in cardiac donors. Clin Transplant. 2009;23:174-177.
Vorlat A, Conraads VM, Jorens PG, et al. Donor B-type natriuretic peptide predicts early cardiac performance after heart transplantation. J Heart and Lung Transplant. 2012;31:579-584.
Dronavalli VB, Ranasinghe AM, Venkateswaran RJ, et al. N-terminal pro-brain-type natriuretic peptide: a biochemical surrogate of cardiac function in the potential heart donor. Eur J Cardiothorac Surg. 2010;38:181-186.
Venkateswaran RV, Ganesh JS, Thekkudan J, et al. Donor cardiac troponin-I: a biochemical surrogate of heart function. Eur J Cardiothorac Surg. 2009;36:286-292.
Venkateswaran RV, Dronavalli V, Lambert PA, et al. The proinflammatory environment in potential heart and lung donors: prevalence and impact of donor management and hormonal therapy. Transplantation. 2009;88:582-588.
Birks EJ, Burton PB, Owen VJ, et al. Elevated tumor necrosis factor-alpha and interleukin-6 in myocardium and serum of malfunctioning donor hearts. Circulation. 2000;102:III352-8.
Birks EJ, Owen VJ, Burton PB, et al. Tumor necrosis factor-alpha is expressed in donor heart and predicts right ventricular failure after human heart transplantation. Circulation. 2000;102:326-331.
Wagner FD, Jonitz B, Potapov EV, et al. Procalcitonin, a donor-specific predictor of early graft failure-related mortality after heart transplantation. Circulation. 2001;104:I192-6.
Potapov EV, Wagner FD, Loebe M, et al. Elevated donor cardiac troponin T and procalcitonin indicate two independent mechanisms of early graft failure after heart transplantation. Int J Cardiol. 2003;92:163-167.
Sung PH, Lin HS, Chen HK, et al. Soluble ST2 is a useful biomarker for grading cerebral-cardiac syndrome in patients after acute ischemic stroke. J Clin Med. 2020;9:489.
Chow SL, Maisel AS, Anand I, et al. Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the american heart association. Circulation. 2017;135:e1054-91.
Januzzi JL, Mebazza A, Di Somma S. ST2 and prognosis in acutely decompensated heart failure: the international ST2 consensus panel. Am J Cardiol. 2015;115:26B-31B.
Felker GM, Fiuzat M, Thompson V, et al. Soluble ST2 in ambulatory patients with heart failure: association with functional capacity and long-term outcomes. Circ Heart Fail. 2013;6:1172-1179.
Galeone A, Lessana A, Mascolo E, et al. Interleukin-1 receptor related protein ST2 and mitral valve repair outcome in patients with chronic degenerative mitral regurgitation. Thorac Cardiovasc Surg. 2014;62:47-51.
Hoogerwerf JJ, Tanck MWT, van Zoelen MAD, Wittebole X, Laterre PF, van der Poll T. Soluble ST2 plasma concentrations predict mortality in severe sepsis. Intensive Care Med. 2010;36:630-637.
Pascual-Figal DA, Garrido IP, Blanco R, et al. Soluble ST2 is a marker for acute cardiac allograft rejection. Ann Thorac Surg. 2011;92:2118-2124.
Januzzi JL, Horne BD, Moore SA, et al. Interleukin receptor family member ST2 concentrations in patients following heart transplantation. Biomarkers. 2013;18:250-256.
Tay SS, Plain KM, Bishop GA. Role of IL-4 and Th2 responses in allograft rejection and tolerance. Curr Opin Organ Transplant. 2009;14:16-22.
Yin H, Li XY, Jin XB, et al. IL-33 prolongs murine cardiac allograft survival through induction of TH2-type immune deviation. Transplantation. 2010;89:1189-1197.